|Year : 2005 | Volume
| Issue : 12 | Page : 547-556
Attention deficit hyperactivity disorder: A review for family physicians
Learning Disability Clinic, Division of Pediatric Neurology, Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India
Learning Disability Clinic, Division of Pediatric Neurology, Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai – 400 022
Source of Support: None, Conflict of Interest: None
Attention deficit hyperactivity disorder (ADHD) is a chronic behavioral disorder characterized by persistent hyperactivity, impulsivity, and inattention that impairs educational achievement and/or social functioning. Its diagnosis is made by ascertaining whether the child's specific behaviors meet the diagnostic and statistical manual of mental disorders-IV-revised criteria. Its etiology is still unclear but recent studies suggest that genetics plays a major role in conferring susceptibility. Comorbidity with psychiatric disorders such as anxiety disorder, depression, oppositional defiant disorder and conduct disorder; and with specific learning disability is not uncommon. Although medication works well in most cases of ADHD, optimal treatment requires integrated medical and behavioral treatment. Methylphenidate (MPH) and atomoxetine are the two drugs being currently prescribed and their efficacy in decreasing the symptoms of ADHD is well documented. Pyschoeducational interventions in school can help increase the successful functioning of affected children and improve their academic performance. Almost half of affected children continue to show significant symptoms of the disorder into adolescence and young adulthood. The family physician can play an important role in detecting this condition early, coordinating its assessment and treatment, counseling the parents and classroom teacher, and monitoring the child's academic and psychosocial progress on a long-term basis.
Keywords: Attention deficit hyperactivity disorder, Family physicians, Primary care
|How to cite this article:|
Karande S. Attention deficit hyperactivity disorder: A review for family physicians. Indian J Med Sci 2005;59:547-56
For over 100 years it has been documented that some children can have excessive and impairing hyperactivity, impulsivity, and inattention. In 1902, the English pediatrician George Still presented a series of three lectures to the Royal Society of Medicine describing 43 children from his clinical practice that were often resistant to discipline, who showed little inhibitory volition, had serious problems with sustained attention and could not learn from the consequences of their actions. He proposed that these significant behavioral problems were due to an underlying neurological deficit and not caused by the environment.
However, it was not till 1968 that the diagnostic and statistical manual of mental disorders (DSM) of the American Psychiatric Association first named this clinical disorder as hyperkinetic impulse disorder (DSM-II). As newer clinical research emerged, the name changed to attention deficit disorder (DSM-III) in 1980, and eventually to attention deficit hyperactivity disorder (ADHD) (DSM-IV) in 1994.,
Diagnosis of ADHD
Family physicians should initiate an evaluation for ADHD when a child presents with symptoms that include academic underachievement and failure, disruptive classroom behavior, inattentiveness, poor self-esteem, or problems with establishing or maintaining social relationships. The diagnosis of ADHD is based on clinical findings and is made by ascertaining whether the child's specific behaviors meet the DSM-IV-R criteria [Table - 1]. These criteria define three subtypes of ADHD: (1) ADHD primarily of the inattentive type (ADHD/I); (2) ADHD primarily of the hyperactive-impulsive type (ADHD/HI); and, (3) ADHD, combined type (ADHD/C).
A child meets the diagnostic criteria for ADHD by documentation of: (1) presence of at least six of the nine behaviors described in the inattentive domain (ADHD/I), or, at least six of the nine behaviors described in the hyperactive/impulsive domain (ADHD/HI), or six of the nine behaviors described in both domains (ADHD/C), and these behaviors should be occurring ''often'' and to a degree that is maladaptive and inconsistent with the child's developmental level [Table - 1]; (2) presence of these behaviors in two or more settings (for example, at home and at school) for at least past 6 months; (3) presence of some symptoms of ADHD before 7 years of age (history from parents); (4) clear evidence of clinically significant impairment in academic or social functioning, or in both; (5) these symptoms not occurring exclusively during the course of a pervasive developmental disorder, schizophrenia, or another psychotic disorder, and not better accounted for by another mental disorder (for example, a mood disorder or an anxiety disorder).
Family physicians should obtain the evidence regarding the core symptoms of ADHD directly from parents and the classroom teacher. Cranial CT/MRI scan, electroencephalogram, and blood tests (e.g., thyroid hormone levels, lead levels) are not necessary for diagnosing ADHD. However, audiometric and ophthalmic examinations should be done to rule out associated hearing and visual deficits, as they are common causes of poor school performance.
Prevalence of attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder is one of the most common behavioral disorders of childhood. Data from Western countries indicate that 6.8% (range 8-12%) of school-going children have ADHD: 3.2% have ADHD-I, 0.6% have ADHD-HI, and 2.9% have ADHD-C., Overall, boys are affected three times more often than girls, but girls are more likely than boys to have the ADHD-I subtype.,
There is no data available from India of prevalence rates of ADHD among elementary school-going children in the general population. However, recent studies from Chandigarh and Kolkata have reported that 8.1 and 15.5% of children referred to the child guidance clinic, respectively, were diagnosed as having ADHD.,
What causes ADHD?
There is no one single unified theory that explains the etiology of ADHD. Recent functional MRI brain studies indicate that the disorder may be caused by atypical functioning in the frontal lobes, basal ganglia, corpus callosum, and cerebellar vermis., Pharmacological studies have also implicated dysregulation of frontal-sub cortical-cerebellar catecholaminergic circuits (dopamine and norepinephrine neurotransmitter systems) in the pathophysiology of the disorder. Family studies have provided strong evidence that genetics plays a major role in conferring susceptibility to ADHD. ,, Studies have indicated that low-birth weight and psychosocial adversity (for example, severe parental discord, low-social class, foster placement) are predisposing risk factors for ADHD., Also, babies born to mothers who consume alcohol or smoke during pregnancy are at risk for ADHD.,
Comorbid conditions and their diagnosis
Family physicians should be aware that between 18% and 35% of children with ADHD have one or more associated psychiatric disorders such as anxiety disorder, depression, oppositional defiant disorder (ODD), and conduct disorder (CD)., Although the family physician may not always be in a position to make a precise diagnosis of these coexisting conditions, evidence for most of them can be easily detected. For example, a family history of anxiety disorders coupled with a patient history characterized by frequent fears and difficulties with separation from caregivers may be suggestive of an anxiety disorder. Frequent sadness and preference for isolated activities should alert the physician to the presence of depressive symptoms. ODD includes persistent symptoms of 'negativistic, defiant, disobedient, and hostile behaviors toward authority figures.' The diagnostic features of CD, a more severe condition, include 'a repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate social norms or rules are violated.' Preliminary studies suggest that ODD and CD are more frequent in children with the ADHD-HI and ADHD-C subtypes, while depression and anxiety disorder are more frequent in children with the ADHD-I and ADHD-C subtypes.,
The Child Behavior Checklist (CBCL) is a useful screening tool for the identification of psychiatric comorbidity in children and adolescents with ADHD in the primary care setting. ,, It is an affordable pencil and paper test completed by the child's caregiver, requiring no administration by a physician. Use, scoring, and pricing information are accessible at: http://www.aseba.org/.,, Referral to a child psychiatrist is necessary when screening suggests psychiatric comorbidity.
Also, up to 15-20% of children with ADHD have associated specific learning disability (SpLD) which is manifested by significant unexpected, specific and persistent difficulties in the acquisition and use of efficient reading (dyslexia), writing (dysgraphia) or mathematical (dyscalculia) abilities despite conventional instruction, intact senses, normal intelligence, proper motivation, and adequate socio-cultural opportunity. Associated SpLD adds to the academic underachievement and failure. Referral to a learning disability clinic is necessary when the academic difficulties are suggestive of SpLD. Psychoeducational testing will be required to determine whether a discrepancy exists between the child's learning potential (intelligence quotient) and actual academic progress (achievement test scores). The clinical psychologist conducts the standard intelligence test viz. Wechsler intelligence scale for children test to determine that the child's intellectual functioning is normal. The special educator assesses the child's academic achievement by administering a standard educational test (for example, wide range achievement test or curriculum-based test) to assess the child's performance in areas such as reading, spelling, written language, and mathematics. An academic achievement of 2 years below the child's actual school grade placement or chronological age is considered diagnostic of SpLD.
Recent data also indicates that girls with ADHD are less likely to have any of this coexisting conditions.
Importance of early diagnosis of ADHD
It is now well recognized that the presence of a child with ADHD results in increased likelihood of disturbances to family and marital functioning, disrupted parent-child relationships and increased levels of parent stress, particularly when ADHD is comorbid with ODD or CD. Even parents of preschool children with ADHD may be under huge stress when their child does not respond to ordinary parental requests and behavioral advice.
If ADHD remains undetected the child may experience academic failure, rejection by peers, and develop low-self-esteem. ,,, Whereas it was previously thought that all children eventually outgrow ADHD, recent studies suggest that 30-60% of affected children continue to show significant symptoms of the disorder into adolescence and young adulthood. ,,,Adolescence may bring about a reduction in the over activity but inattention, impulsiveness, and inner restlessness remain resulting in academic, behavioral, and social impairment. ,,, Among individuals whose symptoms abate during adolescence, the outcome may be similar to that of normal subjects in terms of social functioning, and drug and alcohol use, although not academic achievement.,, Adults with persistent symptoms complete less formal schooling, have lower-status jobs and have higher rates of antisocial personality.,,
If ADHD with coexisting psychiatric conditions remains undetected the prognosis is poorer. Adolescents with ADHD and coexisting depression are at increased risk for suicide attempts. Frequently, children and adolescents with ADHD with persisting ODD later develop symptoms of sufficient severity to qualify for a diagnosis of CD. The frequency of substance-use disorder, mostly not involving alcoholism, is higher among adolescents and young adults with ADHD predominantly among those with coexisting CD. ,,
Thus, it is important to identify ADHD early during childhood, rather than when chronic poor school performance, or problems with strained parent-child relationship or social functioning and their attendant emotional sequelae ensue.
Management of ADHD
The three treatments that have been validated as being significantly effective for ADHD are: (1) medication management, (2) behavioral therapy, and (3) a combination of the two approaches.
(1) Medication management of ADHD : To achieve amelioration of the core ADHD symptoms, medication management is superior to behavioral therapy. MPH and atomoxetine are the two drugs which are being currently prescribed and their efficacy in decreasing the symptoms of ADHD is well documented. ,,,, Medications are not recommended for use in children who are below 6 years of age. ,,,,
Most children with ADHD improve on the stimulant MPH and maintain their improvement without intolerable adverse events. ,, MPH is believed to act on central dopamine and norepinephrine pathways. ,, Short-acting MPH is now available in our country. Its behavioral effects begin within 30 min of oral administration and last for 3-5 h. The daily dose should be individualized by titration and careful monitoring and it ranges from 5 to 20 mg twice daily to three times daily. ,, Side effects include anorexia, stomachache, headache, irritable mood, tics, and sleep difficulties. These side effects, however, are usually mild and responsive to dose adjustment and often abate with continuous use. Continuous use has been associated in some children with slowing of physical growth (approximately 1 cm/year during the first 1-3 years of treatment), which is transient and of unclear cause. ,, In Western countries, long-acting MPH is now available and it permits once-daily administration (18-54 mg) and its behavioral effects last for 10-12 h. Long-acting MPH is used to ensure compliance in children who feel embarrassed to take medication in school.
Atomoxetine a nonstimulant highly selective noradrenaline reuptake inhibitor, is a new drug, which represents an important advance in the pharmacological management of ADHD. ,, Atomoxetine demonstrates efficacy comparable to methylphenidate in the treatment of ADHD. ,, Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief. The starting dose is 0.5 mg/kg/day and increased after 4 days to 1.2-1.4 mg/kg/day. Its most commonly reported adverse effects are transient and include dyspepsia, nausea, vomiting, decreased appetite, and weight loss. ,,
In general, medication is best titrated against desirable effects such as behavioral control, improved educational achievement and peer group relations, and development of intolerable adverse effects. Medication can be discontinued on Sundays and school holidays. Also, periodic (yearly) discontinuation for a brief period (for example, during summer vacations) is often used to reaffirm the need for continuing medication.
Additional pharmacological options include the antidepressants: bupropion and desipramine; and the antihypertensives: clonidine and guanfacine. But the scientific base supporting the efficacy of these drugs is limited. Another stimulant drug, pemoline, although effective is no longer used because of its potential to cause serious hepatotoxicity.
(2) Behavioral therapy : Parents are taught by psychologists or social workers to achieve consistent and positive interactions with their affected child. They are taught how to reinforce positive behaviors by praise or by using daily contingency charts (star or 'happy face' charts), how to extinguish negative behaviors by active ignoring, and how to effectively punish for intolerable behaviors. Parent training is the sole treatment for children with ADHD who are below 6 years of age.
Simple pyschoeducational interventions at school such as seating the child near the teacher to minimize classroom distractions, or assigning a specific teacher to review daily assignments with the child have been shown to be effective in improving the behavior and academic performance of affected children.
(3) Combined treatment : Optimal treatment of ADHD requires integrated medical and behavioral (combined) treatment. Although combined treatment does not yield significantly greater benefits than medication management for core ADHD symptoms, it helps reduce the total daily required medication dose and the associated non-ADHD symptoms viz. symptoms of anxiety and depression, and oppositional/aggressive behaviors; and helps achieve positive functioning outcomes for peer interactions, parent-child relations, and reading achievement. Recent research suggests that combined treatment may help prevent the development of future psychiatric disorders.
Management of associated SpLD
The cornerstone of treatment of SpLD is remedial education. The child has to undergo remedial education sessions twice or thrice weekly for a few years to achieve academic competence., The child should also avail the required provisions (accommodations) to help cope up in a regular mainstream school, e.g. exemption from spelling mistakes, availing extra 30 min for all written tests, dropping a second language and substituting it with work experience, dropping algebra and geometry and substituting them with lower grade of mathematics, and work experience.,
Important role of family physician
Every family physician can facilitate early detection of ADHD by enquiring during a consultation whether the child has problems in learning at school, and specifically asking the parents whether they are concerned about their child's behavior in school, or at home. The family physician can play a crucial role in coordinating the assessment (obtaining information of child's behavior from parents and classroom teacher) and treatment (prescribing ongoing medication once the patient is stabilized, and ensuring compliance) of ADHD. Those familiar with its management can even initiate the medication management, but will need to liaise with a child psychiatrist/developmental pediatrician regarding any complications in treatment (for example, intolerable side effects or treatment failure) or if comorbid conditions (ODD, CD, anxiety, depression, SpLD) are suspected.
It is well known that favorable outcome of ADHD is dependent on a supportive home and school environment. The family physician can play an important role in counseling the parents and classroom teacher of a child with ADHD about the need for medication, psychoeducational interventions, analyze their feedback about the child's specific target behaviors to titrate the medication dose, and monitor the child's academic progress on a long-term basis.
Parents of a child with ADHD may consult their family physician about the utility of unconventional therapies such as cognitive treatments, individual psychotherapy, play therapy, restrictive or supplemental diets, mineral or amino acid supplements, megavitamins, herbal medicines, homeopathy, allergy treatments, neurofeedback, and vestibular and sensorimotor integration to treat their child's disorder. None of these have proved to be effective when subjected to double-blind controlled clinical trials. ,,,,, The family physician can help parents become better-informed consumers.
To conclude, every family physician can play a crucial role in ensuring that no child with ADHD loses out in life.
| ¤ References|| |
|1.||Still GF. The Goulstonian lectures on some abnormal psychical conditions in children. Lancet 1902;1:1008-12, 1077-82, 1163-8. |
|2.||American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 2nd ed. Washington, DC: American Psychiatric Association; 1968. |
|3.||American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC: American Psychiatric Association; 1980. |
|4.||American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994. |
|5.||American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-70. |
|6.||American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. rev. Washington, DC: American Psychiatric Association; 2000. |
|7.||Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001;107:e43. |
|8.||Wolraich M, Hannah JN, Baumgaertel A, Pinnock TY, Feurer I. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Dev Behav Pediatr 1998;19:162-8. |
|9.||Malhi P, Singhi P. Spectrum of attention deficit hyperactivity disorders in children among referrals to psychology services. Indian Pediatr 2000;37:1256-60. |
|10.||Mukhopadhyay M, Misra S, Mitra T, Niyogi P. Attention deficit hyperactivity disorder. Indian J Pediatr 2003;70:789-92. |
|11.||Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A 1998;24;95:14494-9. |
|12.||Giedd JN, Blumenthal J, Molloy E, Castellanos FX. Brain imaging of attention deficit/hyperactivity disorder. Ann N Y Acad Sci 2001;931:33-49. |
|13.||Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996;35:264-72. |
|14.||Waldman ID, Rowe DC, Abramowitz A, Kozel ST Mohr JH, Sherman SL, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998;63:1767-76. |
|15.||Barr CL, Wigg KG, Bloom S, Schachar R, Tannock R, Roberts W, et al. Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Am J Med Genet 2000;96:262-7. |
|16.||Bakker SC, van der Meulen EM, Buitelaar JK, Sandkuijl LA, Pauls DL, Monsuur AJ, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003;72:1251-60. |
|17.||Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002;23:16-22. |
|18.||Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, Mick E, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:1495-503. |
|19.||Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 2002;41:378-85. |
|20.||Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 2003;160:1028-40. |
|21.||Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:525-40, vii. |
|22.||Busch B, Biederman J, Cohen LG, Sayer JM, Monuteaux MC, Mick E, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr Serv 2002;53:1103-11. |
|23.||Achenbach TM. Manual for the Child Behavior Checklist/4-18 and the 1991 Profile. Burlington, VT: University of Vermont, Department of Psychiatry; 1991. |
|24.||Biederman J, Faraone SV, Doyle A, Lehman BK, Kraus I, Perrin J, Tsuang MT. Convergence of the Child Behavior Checklist with structured interview-based psychiatric diagnoses of ADHD children with and without comorbidity. J Child Psychol Psychiatry 1993;34:1241-51. |
|25.||Biederman J, Monuteaux MC, Greene RW, Braaten E, Doyle AE, Faraone SV. Long- term stability of the Child Behavior Checklist in a clinical sample of youth with attention deficit hyperactivity disorder. J Clin Child Psychol 2001;30:492-502. |
|26.||Kulkarni M, Kalantre S, Upadhye S, Karande S, Ahuja S. Approach to learning disability. Indian J Pediatr 2001;68:539-46. |
|27.||Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36-42. |
|28.||Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001;4:183-207. |
|29.||DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention- deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 2001;40:508-15. |
|30.||Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:711-26. |
|31.||Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998;155:493-8. |
|32.||Bagwell CL, Molina BS, Pelham WE Jr, Hoza B. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 2001;40:1285-92. |
|33.||Mannuzza S, Klein RG, Moulton JL 3rd. Persistence of attention deficit/hyperactivity disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord 2003;7:93-100. |
|34.||Brent DA, Perper JA, Goldstein CE, Kolko DJ, Zelenak JP Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988;45:581-8. |
|35.||Waxmonsky J. Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr 2003;15:476-82. |
|36.||The MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86. |
|37.||Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001;165:1475-88. |
|38.||Reeves G, Schweitzer J. Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother 2004;5:1313-20. |
|39.||Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003;4:1165-74. |
|40.||Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004;24:1020-36. |
|41.||Pelham WE Jr, Fabiano GA. Behavior modification. Child Adolesc Psychiatr Clin N Am 2000;9:671-88, ix. |
|42.||Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry 2001;40:402-8. |
|43.||Hoffman JB, DuPaul GJ. Psychoeducational interventions for children and adolescents with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:647-61, ix. |
|44.||Dakin KE. Educational assessment and remediation of learning disabilities. Semin Neurol 1991; 11:42-9. |
|45.||Abikoff H, Gittelman R. Hyperactive children treated with stimulants: is cognitive training a useful adjunct? Arch Gen Psychiatry 1985;42:953-61. |
|46.||Wender EH. The food additive-free diet in the treatment of behavior disorders: a review. J Dev Behav Pediatr 1986;7:35-42. |
|47.||Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998;27:190-205. |
|48.||Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit hyperactivity disorder. N Engl J Med 1999;340:780-8. |
|49.||Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001;139:189-96. |
|50.||Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002;23 Suppl 1:S37-45. |
[Table - 1]
|This article has been cited by|
||Attention Deficit Hyperactivity Disorder
| ||Madhuri Kulkarni |
| ||The Indian Journal of Pediatrics. 2014; |
||Packages of care for attention-deficit hyperactivity disorder in low- and middle-income countries
| ||Flisher, A.J., Sorsdahl, K., Hatherill, S., Chehil, S. |
| ||PLoS Medicine. 2010; 7(2): e1000235 |
|| Family approach to disruptive behavior disorder in childhood | [Abordaje familiar del trastorno de comportamiento perturbador en la infancia]
| ||Jiménez Barbero, J.A., Pérez García, M., Navarro Mateu, F., Medina Garrido, L., Almela Bernal, J. |
| ||Acta Pediatrica Espanola. 2010; 68(3): 119-123 |
||South African teachersæ experiences of children in their classrooms who may have ADHD
| ||Lopes, T., Eloff, I., Howie, S., Maree, J.G. |
| ||Journal of Psychology in Africa. 2009; 19(3): 347-354 |
||Attention deficit/hyperactivity disorder (ADHD) in adults
| ||Jacob, R., Chowdhury, A.N., Ganesan, J. |
| ||Indian Journal of Medical Research. 2009; 129(4): 458-459 |
||Psicofamiliar alternative treatment of behavior problems: Parentæs school | [Alternativa psicofamiliar al tratamiento precoz de los problemas de conducta: La escuela de padres]
| ||Jiménez Barbero, J.A., Pérez García, M., Fernández Galindo, F.J., Díaz García, I. |
| ||Anales de Psiquiatria. 2009; 25(3): 142-145 |
||Parameters of stress and trait anxiety scores in teenagers brought up in socially favorable and socially adverse conditions
| ||Airapetyants, M.G., Shkolnik, T.K., Luschekina, E.A. |
| ||Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I.P. Pavlova. 2007; 57(3): 261-267 |
||Endocrinology and metabolism 2006: Editorial comments
| ||Root, A.W. |
| ||Current Opinion in Pediatrics. 2006; 18(4): 423-426 |